Bayer aims for new Xarelto nod in Japan; Purdue recruits first chief commercial officer; Durata med wins FDA clearance;

> Bayer submitted its clot-fighter Xarelto for approval in Japan, to treat deep vein thrombosis and pulmonary embolism. Report

> Purdue Pharma tapped Saeed Motahari, formerly an AbbVie ($ABBV) VP of sales and marketing, to be its first chief commercial officer. Report

> Durata Therapeutics won FDA approval for its new drug to treat serious bacterial skin infections, Dalvance. Report

> The New York-based health communications group Chandler Chicco Companies, part of inVentiv Health, expanded its digital team with three new senior-level hires. Report

> Hungary's Richter agreed to buy a 51% stake in Mediplus, a Curacao-based company that promotes its products in Latin America. Report

And Finally... The use of antidepressants in England has risen faster than ever since the recession there boosted unemployment. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.